# US 2024/0189245 A1 · Cyclosporine compositions and methods of use thereof

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2024/0189245 A1
- Document ID: US20240189245A1
- Status: Published application
- Kind: A1
- Application number: 18/287,762
- Filed: 2022-06-14
- Published: 2024-06-13
- Earliest claimed: 2021-06-14
- Applicants: ProTransit Nanotherapy LLC
- Inventors: Gary L. Madsen; Christopher L. Porter
- Web page: https://patentgrep.com/patent/US20240189245A1

## CPC

- A61K 9/1075: {Microemulsions or submicron emulsions; Preconcentrates or solids thereof; Micelles, e.g. made of phospholipids or block copolymers (A61K9/0026 takes precedence)}
- A61K 9/5153: {Polyesters, e.g. poly(lactide-co-glycolide)}
- A61K 8/0241: {Containing particulates characterized by their shape and/or structure (see also A61K8/04, A61K8/11, and A61K8/14, further aspects are classified in A61K2800/40 and subcodes)}
- A61K 8/37: Esters of carboxylic acids
- A61K 8/64: Proteins; Peptides; Derivatives or degradation products thereof
- A61K 8/8129: {Compositions of homopolymers or copolymers of compounds having one or more unsaturated aliphatic radicals, each having only one carbon-to-carbon double bond, and at least one being terminated by an alcohol, ether, aldehydo, ketonic, acetal or ketal radical; Compositions of hydrolysed polymers or esters of unsaturated alcohols with saturated carboxylic acids; Compositions of derivatives of such polymers, e.g. polyvinylmethylether}
- A61K 8/85: Polyesters
- A61K 9/0014: {Skin, i.e. galenical aspects of topical compositions (non-active ingredients are additionally classified in A61K47/00; A61K9/0009, A61K9/0021, A61K9/7015, A61K9/7023 take precedence; cosmetic preparations A61K8/00, A61Q; preparations for wound dressings or bandages A61L26/00)}
- A61K 9/0048: {Eye, e.g. artificial tears}
- A61K 9/5123: {Organic compounds, e.g. fats, sugars}
- A61K 9/5138: {obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates}
- A61K 38/13: Cyclosporins
- A61K 45/06: Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A61P 17/06: Antipsoriatics
- A61Q 7/00: Preparations for affecting hair growth
- A61K 2800/413: Nanosized, i.e. having sizes below 100 nm
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61Q: SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS

## Abstract

Cyclosporine containing nanoparticles and methods for making and using the same are provided.

## Claims

### Claim 1

A nanoparticle comprising cyclosporine, a biodegradable polymer, a surfactant emulsifier, and a plasticizer.

### Claim 2 (depends on 1)

The nanoparticle of claim 1, wherein said biodegradable polymer is poly-lactic-co-glycolic acid.

### Claim 3 (depends on 1)

The nanoparticle of claim 1, wherein said plasticizer is dimethyl tartrate.

### Claim 4 (depends on 1)

The nanoparticle of claim 1, wherein said emulsifier is polyvinyl alcohol.

### Claim 5 (depends on 1)

The nanoparticle of claim 1 comprising cyclosporine, poly-lactic-co-glycolic acid, dimethyl tartrate, and polyvinyl alcohol.

### Claim 6 (depends on 1)

A composition comprising the nanoparticle of claim 1 and a pharmaceutically acceptable carrier.

### Claim 7 (depends on 1)

A method of treating, inhibiting, and/or preventing hair loss and/or regrowing and/or thickening hair in a subject in need thereof, said method comprising topically administering the nanoparticle of claim 1 to the skin of the subject.

### Claim 8 (depends on 7)

The method of claim 7, wherein said hair loss is caused by alopecia, alopecia areata, androgenetic alopecia, hypotrichosis, or hair miniaturization.

### Claim 9 (depends on 7)

The method of claim 7, further comprising administering at least one other hair regrowth agent or at least one antioxidant.

### Claim 10 (depends on 1)

A method of treating, inhibiting, and/or preventing psoriasis in a subject in need thereof, said method comprising topically administering the nanoparticle of claim 1 to the skin of the subject.

### Claim 11 (depends on 1)

A method of treating, inhibiting, and/or preventing arthritis in a subject in need thereof, said method comprising topically administering the nanoparticle of claim 1 to the skin of the subject.

### Claim 12 (depends on 1)

A method of treating, inhibiting, and/or preventing dry eye disease in a subject in need thereof, said method comprising administering the nanoparticle of claim 1 to the eye of the subject.
